- In April 2023, Zoetis Inc., a global leader in animal health, announced the launch of an extended-release injectable buprenorphine formulation for post-operative pain management in cats, marking a significant step toward improving pain control in companion animals. This innovation enhances compliance and reduces the need for repeated dosing, reinforcing Zoetis's commitment to advancing veterinary analgesia
- In March 2023, Elanco Animal Health Incorporated partnered with veterinary clinics across the U.S. to conduct real-world evaluations of multimodal pain management strategies that include opioid use. The initiative aims to gather clinical data to optimize dosing regimens, improve animal outcomes, and address concerns over controlled substance handling in veterinary settings
- In March 2023, Boehringer Ingelheim introduced a global awareness campaign highlighting the importance of pain management in pets, with a specific focus on the responsible use of veterinary opioids. This campaign is targeted at both veterinarians and pet owners, promoting education around recognizing pain symptoms and the benefits of appropriate opioid therapies
- In February 2023, Dechra Pharmaceuticals announced its investment in research for transdermal opioid delivery systems aimed at minimizing stress in animals during administration. The research is being conducted in partnership with several academic institutions and has the potential to significantly improve the ease and safety of opioid use in veterinary care
- In January 2023, VetOne, a prominent supplier of veterinary products, launched its generic version of tramadol hydrochloride tablets for use in dogs under veterinary prescription. This move increases market access to affordable opioid options, especially in small animal practices, and underscores the growing demand for cost-effective analgesic solutions in veterinary medicine
